VBI VACCINES INC. (TSE:VBV) Files An 8-K Other EventsItem 8.01 Other Events.
On November 2, 2017, VBI Vaccines Inc. (the “Company”) issued a press release announcing the appointment, effective as of October 30, 2017, of Ran Nussbaum, co-founder and managing partner of The Pontifax Group, to the Company’s board of directors. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No | Description |
| 99.1 | Press Release dated November 2, 2017 |
VBI Vaccines Inc/BC ExhibitEX-99.1 2 ex99-1.htm VBI Vaccines Strengthens Board of Directors with Appointment of Ran Nussbaum ● Ran Nussbaum,…To view the full exhibit click here
About VBI VACCINES INC. (TSE:VBV)
VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).
